Core Viewpoint - *ST Changyao has been subjected to an investigation by the China Securities Regulatory Commission (CSRC) due to suspected false financial reporting, which could lead to a forced delisting if significant violations are confirmed [2]. Financial Performance - As of December 31, 2024, *ST Changyao reported a negative net asset of -433 million yuan and an undistributed profit of -1.59 billion yuan [2]. - For the first three quarters of 2025, the company's revenue increased by 4.40% year-on-year to 105 million yuan, while the net profit attributable to shareholders decreased by 15.89% to -210 million yuan [2]. - The net profit excluding non-recurring items fell by 16.99% year-on-year to -209 million yuan, with net assets dropping to -643 million yuan [2]. Stock Performance - As of November 7, *ST Changyao's stock price was 3.45 yuan per share, reflecting a decline of 0.58%, with a total market capitalization of 1.209 billion yuan [2][3].

Core Viewpoint - *ST Changyao has been under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which could lead to significant legal consequences and potential delisting if major violations are confirmed [1]. Financial Performance Summary - As of December 31, 2024, *ST Changyao reported a negative net asset of -433 million yuan and an undistributed profit of -1.59 billion yuan [1]. - For the first three quarters of 2025, the company experienced a revenue increase of 4.40% year-on-year, reaching 105 million yuan; however, the net profit attributable to shareholders decreased by 15.89% to -210 million yuan, and the non-recurring net profit fell by 16.99% to -209 million yuan [1]. - The net asset value as of the reporting period was -643 million yuan [1]. Stock Market Performance - As of November 7, *ST Changyao's stock price was 3.45 yuan per share, reflecting a decrease of 0.58%, with a total market capitalization of 1.209 billion yuan [2]. - The trading volume was 75,300 shares, with a turnover rate of 2.15% [2]. - The stock has a price-to-earnings (PE) ratio of -4.32 and a price-to-book (PB) ratio of -1.88 [2].

Core Viewpoint - *ST Changyao is facing a critical survival challenge due to the China Securities Regulatory Commission's investigation, the looming risk of delisting, and difficulties in its pre-restructuring process [2][3][4] Financial Situation - As of December 31, 2024, *ST Changyao reported a negative net asset of -433 million yuan and an accumulated loss of -1.59 billion yuan, with a net profit of -628 million yuan for the year [4] - The company's revenue has drastically declined from 1.615 billion yuan in 2022 to 1.198 billion yuan in 2023, and further down to only 112 million yuan in 2024 [5] - For the first three quarters of 2025, *ST Changyao's revenue increased by 4.4% year-on-year to 105 million yuan, but the net profit decreased by 15.89% to -210 million yuan [5] Delisting Risk - The company is under significant threat of mandatory delisting due to its negative net asset situation and the potential for administrative penalties from the CSRC [2][3][6] - If *ST Changyao fails to improve its financial performance in Q4 2025, it will trigger the delisting clause related to negative net assets [6] Restructuring Challenges - Prior to the CSRC investigation, *ST Changyao was already struggling with debt, leading to the initiation of pre-restructuring by the Hubei Province Shiyan Intermediate People's Court on January 20, 2025 [7] - The court has extended the pre-restructuring period until January 20, 2026, indicating slow progress in the restructuring efforts [8] - The company has warned of the uncertainty surrounding its ability to enter formal restructuring and the risk of bankruptcy if restructuring fails [9] Legal and Financial Liabilities - Due to overdue debts, several creditors have initiated lawsuits against *ST Changyao, resulting in the freezing of numerous bank accounts and asset seizures [11] - As of October 20, 2025, the company had significant interest-bearing liabilities totaling 1.106 billion yuan, with 390 million yuan overdue [11] - The company is involved in 140 legal cases with a total amount in dispute of 1.878 billion yuan, which is 434% of its latest audited net assets [11] Market Performance - As of November 7, 2025, *ST Changyao's stock price was 3.45 yuan per share, with a total market capitalization of only 1.209 billion yuan [13]

Core Viewpoint - *ST Changyao is facing a critical situation due to a formal investigation by the China Securities Regulatory Commission (CSRC) for suspected financial data falsification, which may lead to mandatory delisting risks and ongoing pre-restructuring challenges [2][4]. Financial Risks - The company has been under the shadow of delisting due to severe financial issues, with a negative net asset value of -433 million yuan as of December 31, 2024, and an accumulated loss of -1.59 billion yuan [7]. - Revenue has drastically declined from 1.615 billion yuan in 2022 to 1.198 billion yuan in 2023, with projections of only 112 million yuan for 2024 [8]. - For the first three quarters of 2025, the company reported a 4.4% year-on-year revenue increase to 105 million yuan, but net profit decreased by 15.89% to -210 million yuan [8]. Delisting Risks - If *ST Changyao fails to improve its financial performance in Q4 2025, it will trigger the delisting clause due to negative audited net assets [9]. - The company has been under a delisting risk warning since April 22, 2025, following a negative net asset report for the 2024 fiscal year [6]. Pre-restructuring Challenges - Prior to the CSRC investigation, *ST Changyao was already struggling with debt, leading to a pre-restructuring process initiated by the Hubei Province Shiyan Intermediate People's Court on January 20, 2025 [11]. - The court has extended the pre-restructuring period until January 20, 2026, indicating difficulties in the restructuring process [11]. - The company has warned of the risk of bankruptcy if the restructuring fails, despite several subsidiaries already undergoing restructuring [13][14]. Legal and Financial Liabilities - The company faces significant legal challenges, with 140 lawsuits involving a total of 1.878 billion yuan, which is 434% of its latest audited net assets [15]. - As of October 20, 2025, *ST Changyao reported total interest-bearing liabilities of 1.106 billion yuan, with 390 million yuan overdue [15]. - A substantial number of bank accounts (67.7%) have been frozen due to overdue debts, severely impacting the company's financial operations [15][16]. Market Performance - As of November 7, 2025, *ST Changyao's stock price was 3.45 yuan per share, with a total market capitalization of 1.209 billion yuan [17].

Core Viewpoint - *ST Changyao has been under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which could lead to significant legal consequences and potential delisting of its stock [2][5][9] Financial Performance - The company's financial performance has deteriorated significantly, with operating revenue dropping from 16.15 billion in 2022 to 1.12 billion in 2024, a decline of over 90% [5] - The net assets of *ST Changyao were reported at -4.33 billion at the end of 2024 and further declined to -6.43 billion by the end of Q3 2025, indicating an imminent risk of financial delisting [2][5] - The company has incurred substantial losses, with net profits excluding non-recurring items reported at -6.32 billion in 2023 and -5.69 billion in 2024 [5] Debt and Legal Issues - As of Q3 2025, *ST Changyao has significant overdue debts totaling 3.9 billion out of 11 billion in interest-bearing liabilities, with 140 ongoing lawsuits involving a total amount of 18.8 billion [5][7] - The company has had 67.7% of its bank accounts frozen, totaling 109 accounts, due to these legal and financial issues [5] Compliance and Governance - The company has a history of regulatory violations, including unauthorized financial assistance and guarantees, as well as failure to disclose significant lawsuits and overdue debts in a timely manner [7] - Specific violations include providing 1.8 billion in financial assistance to a related party, which constituted 92% of the latest audited net assets, and failing to disclose 25 lawsuits totaling 2.02 billion from May 2021 to May 2023 [7] Restructuring and Delisting Risks - The company is currently undergoing pre-restructuring proceedings initiated by the Shiyan Intermediate People's Court, but its potential for successful restructuring is uncertain due to the ongoing investigation and financial issues [9] - If the CSRC confirms the violations, *ST Changyao may face mandatory delisting under the Shenzhen Stock Exchange's rules for significant legal infractions [9]

11月7日，长江医药控股股份有限公司(以下简称"*ST长药（300391）")公告称，公司收到中国证监会下 发的《立案告知书》，因公司涉嫌定期报告等财务数据虚假记载，根据《中华人民共和国证券法》《中 华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 公告显示，若后续经中国证监会行政处罚认定的事实，触及《深圳证券交易所创业板股票上市规则》规 定的重大违法强制退市情形，*ST长药股票将被实施重大违法强制退市。 而回溯公司过往公告，诸多风险隐患早已显现，叠加此次财务真实性相关的立案调查，*ST长药的经营 与资本层面均已陷入多重危机，广大投资者应充分评估相关风险。 在经营陷入困境的同时，*ST长药的内控漏洞也不断暴露，多次发生违规操作且未履行信息披露义务。 经营状况持续恶化 具体来看，在资金管理方面，截至2023年末，公司向时任董事、总经理罗明控制的企业累计违规提供财 务资助1.8亿元，该金额占公司最近一期经审计净资产的92%，尽管这笔资金在2024年通过关联方债权 债务转让等方式收回，但违规行为已严重违反规范运作要求。 此外，公司控股孙公司还曾未经审议便对外提供809.2万元的关联担保，占最近一期经审 ...

Core Points - Company received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false financial reporting [1] - The investigation is related to the company's periodic reports and financial data [1] - If the investigation leads to a determination of significant violations, the company may face mandatory delisting due to serious misconduct [1]

Group 1 - The company *ST Changyao received a notice from the China Securities Regulatory Commission (CSRC) on November 7, 2025, regarding an investigation due to suspected false reporting of financial data [1] - The CSRC has decided to initiate a case against the company, which may lead to significant legal consequences [1] - If the investigation confirms major violations, the company’s stock may face mandatory delisting due to serious legal infractions [1]

Core Viewpoint - *ST Changyao has been notified by the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false reporting of financial data, which could lead to significant legal consequences including potential delisting of its stock [1] Group 1: Investigation Details - On November 7, 2025, *ST Changyao received a "Notice of Investigation" from the CSRC due to allegations of false records in periodic reports [1] - The CSRC's decision to initiate an investigation indicates serious concerns regarding the company's financial disclosures [1] Group 2: Potential Consequences - If the investigation confirms major violations, the company may face mandatory delisting from the stock market [1] - The company has stated its commitment to cooperate with the CSRC during the investigation and will adhere to regulatory disclosure requirements [1]

Core Viewpoint - The company *ST长药 (300391.SZ) has received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected false reporting of financial data, which may lead to severe penalties and potential delisting from the Shenzhen Stock Exchange if found guilty [1] Summary by Relevant Sections - **Investigation Details** - The company was notified on November 7, 2025, about the investigation due to allegations of false financial reporting [1] - The CSRC's decision to initiate the investigation is based on relevant laws and regulations [1] - **Potential Consequences** - If the CSRC confirms the allegations and determines that they constitute a major violation under the revised Shenzhen Stock Exchange listing rules (2025), the company may face mandatory delisting [1]